Feasibility and Effectiveness of Tele-diabetes Remote System on Glycemic Control and Quality of Life of Children and Youth With Type 1 Diabetes

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age1-25
SponsorSheba Medical Center

About this trial

The goal of this clinical trial is to examine the feasibility and effectiveness of a tele-diabetes remote monitoring system on managing type 1 diabetes (T1DM) among children and adolescents. The study aims to assess whether this system, which incorporates a WhatsApp-based alert system, can improve clinical outcomes, increase adherence to treatment, enhance quality of life, and reduce healthcare utilization in this population. The main questions it aims to answer are:

Does the tele-diabetes remote system improve glycemic control (e.g., time in range \[TIR\], frequency of hypoglycemia and hyperglycemia, HbA1c levels)? Does it enhance adherence to treatment and overall quality of life for children and youth with T1DM? Does the system reduce the number of emergency room visits for diabetic ketoacidosis (DKA) or severe hypoglycemia, hospitalizations, and overall medical costs? Researchers will compare participants who receive WhatsApp notifications (intervention group) with those receiving standard care (control group) to evaluate differences in clinical outcomes, quality of life, and healthcare burden.

Participants will:

Receive notifications via WhatsApp messages sent by a system developed by the research team, which monitors glucose trends in real-time and sends alerts when patterns (e.g., hypoglycemia, hyperglycemia) are detected.

Participate in follow-ups supported by the hybrid medical team between routine clinic visits.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Participants must have a confirmed diagnosis of Type 1 Diabetes Mellitus (T1DM).

Participants must use Dexcome Continuous Glucose Monitoring (CGM)

Must have access to a smartphone capable of receiving WhatsApp messages.

Participants must use a closed-loop insulin pump system (also known as an artificial pancreas system) omnipod DIY or Tandem.

Disqualifiers

Participants who are not using Dexcome Continuous Glucose Monitoring (CGM) and a closed-loop insulin pump system

Trial design

Design model

Parallel

Treatments tested in this trial

  • Tele-diabetes Remote System

    Behavioral

    The tele-diabetes system is a digital platform designed for remote glucose monitoring in patients with Type 1 Diabetes. The system utilizes a smart algorithm to analyze real-time glucose levels, detect trends of hyperglycemia or hypoglycemia, and send automated WhatsApp alerts to participants. These alerts provide actionable insights aimed at improving glycemic control and treatment adherence between routine clinic visits. The system also includes a monitoring dashboard accessed by researchers and clinicians, enabling them to track the alerts sent. The medical team follows a structured escalation protocol: After two consecutive alerts: A registered dietitian contacts the participant to provide personalized dietary and behavioral guidance. If an additional alert is detected after this contact: A virtual physician consultation is scheduled to adjust treatment as needed. If another alert follows: The participant is invited for an in-clinic visit for detailed evaluation and intervention

Treatment groups

100 Participants
are divided into 2 treatment groups
Group A: interventionExperimental treatment 1 intervention
Group B: ControlNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Glycemic control

CGM data - TIR - time in range, TIIR- time in tight range , hypoglycemia and hyperglycemia events, GMI, CV

Time frame
Baseline (prior to receipt of the first WhatsApp alert) and monthly assessments after the first alert, at 1 month, 2 months, and 3 months post-enrollment.

Secondary outcomes

1

Adherence to Treatment

Time of CGM use

Time frame
Baseline (prior to receipt of the first WhatsApp alert) and monthly assessments after the first alert, at 1 month, 2 months, and 3 months post-enrollment.
2

Number of emergency room visits with diabetic ketoacidosis (DKA) or hypoglycemia

Number of emergency room visits with diabetic ketoacidosis (DKA) or hypoglycemia

Time frame
Baseline (prior to receipt of the first WhatsApp alert) and monthly assessments after the first alert, at 1 month, 2 months, and 3 months post-enrollment.
3

Satisfaction score

A satisfaction questionnaire of the digital tool

Time frame
3 months post-enrollment.
4

Number of hospitalizations

Number of hospitalizations

Time frame
3 months past enrollment

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.